Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

accord healthcare s.l.u. - dasatinibas - precursor cell lymphoblastic leukemia-lymphoma; leukemia, myelogenous, chronic, bcr-abl positive - antinavikiniai vaistai - dasatinib accordpharma is indicated for the treatment of adult patients with: newly diagnosed philadelphia chromosome positive (ph+) chronic myelogenous leukaemia (cml) in the chronic phase.  chronic, accelerated or blast phase cml with resistance or intolerance to prior therapy including imatinib.  ph+ acute lymphoblastic leukaemia (all) and lymphoid blast cml with resistance or intolerance to prior therapy. dasatinib accordpharma is indicated for the treatment of paediatric patients with: newly diagnosed ph+ cml in chronic phase (ph+ cml-cp) or ph+ cml-cp resistant or intolerant to prior therapy including imatinib.  newly diagnosed ph+ all in combination with chemotherapy.

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - ponatinib - leukemia, myeloid; leukemia, lymphoid - antineoplastic agents, protein kinase inhibitors - iclusig is indicated in adult patients withchronic phase, accelerated phase, or blast phase chronic myeloid leukaemia (cml) who are resistant to dasatinib or nilotinib; who are intolerant to dasatinib or nilotinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutationphiladelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) who are resistant to dasatinib; who are intolerant to dasatinib and for whom subsequent treatment with imatinib is not clinically appropriate; or who have the t315i mutation. Žr. 4 skyrius. 2 assessment of cardiovascular status prior to start of therapy and 4. 4 situations where an alternative treatment may be considered.

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

as grindeks - paracetamolis - tabletės - 500 mg - paracetamol

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

viasana, uab - sunitinibas - kietosios kapsulės - 25 mg - sunitinib

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

viasana, uab - sunitinibas - kietosios kapsulės - 50 mg - sunitinib

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

lv system service sia - sunitinibas - kietosios kapsulės - 50 mg - sunitinib

Europos Sąjunga - lietuvių - EMA (European Medicines Agency)

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antinavikiniai vaistai - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

teva b.v. - sunitinibas - kietosios kapsulės - 12,5 mg; 50 mg - sunitinib

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

sandoz d.d. - sunitinibas - kietosios kapsulės - 12,5 mg - sunitinib

Lietuva - lietuvių - SMCA (Valstybinė vaistų kontrolės tarnyba)

sandoz d.d. - sunitinibas - kietosios kapsulės - 25 mg - sunitinib